Fig. 7: Validation of the SREBF1 inhibitor Betulin’s ability to promote ferroptosis in prostate cancer cells.
From: SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance
qRT-PCR analysis of the expression of some SREBF1 target genes and ferroptosis-related genes in LNCaP (A) and PC3 (B) cell lines (n = 3). Fluorescence microscopy observation of ROS content in LNCaP (C) and PC3 (D) cells. Hoechst was used to stain the nuclei, and ROS was visualized using the DCFH-DA probe (n = 3). Cell flow cytometry analysis of ROS content in LNCaP (E) and PC3 (F) cells. Quantitative comparison by Mean Fluorescence Intensity (MFI) (n = 3). G Measurement of GSH content in LNCaP and PC3 cells (n = 6). H Cell viability assay in LNCaP cells after androgen deprivation culture and Betulin treatment. The left y-axis represents cell viability, and the right y-axis represents the Q value calculated for each concentration group (n = 3). CS charcoal Stripped. Data were presented as mean ± SD. (ns, P ≥ 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
